A large share of the questions people ask about ibogaine concern conditions it has never been studied for. Parkinson's disease, multiple sclerosis, obsessive-compulsive disorder, bipolar disorder, eating disorders, epilepsy, chronic pain and attention disorders all generate steady interest, and for every one of them the human evidence base is empty.
This entry sets that out directly, because an honest no is more useful than a hedge. It also makes a point that is easy to miss: several of these conditions appear in the ibogaine literature not as things the drug was tested on, but as reasons people were excluded from the studies.
Why this list exists
Interest in these conditions is not unreasonable. Ibogaine is described as affecting neuroplasticity, it produces a profound psychological experience, and the reported effects in post-traumatic stress and depression were large. Any of those could support a hypothesis that it might help in other neurological or psychiatric conditions.
A hypothesis is where it stops. Moving from a plausible idea to a treatment requires studies that have not been done, and in the meantime a plausible idea provides no information about whether the treatment would help, do nothing, or cause harm in a given condition.
There is also a reason the list is worth publishing rather than simply leaving unaddressed. Someone searching for ibogaine and a specific condition will find pages willing to answer confidently, and those pages are not generally constrained by what has been measured. A plainly stated absence, with the reasoning behind it, is the only thing that competes with a confidently invented presence.
What has actually been studied
The human evidence base is narrow and well defined. A 2026 review covering human studies published between 1990 and early 2025 examined 24 studies and 38 case reports and series, and describes observational data suggesting ibogaine may ease symptoms of opioid use disorder, post-traumatic stress disorder or polysubstance dependence [1]. It also notes that no double-blind randomised trial has shown ibogaine or noribogaine effective for opioid use disorder, and that most positive data come from uncontrolled, open-label or retrospective studies at high risk of bias [1].
Alongside those indications sit alcohol use disorder, where a small pilot exists, and the veteran cohort in which depression and anxiety were measured as secondary outcomes alongside post-traumatic stress [3]. That is the complete list of conditions with any human ibogaine data. Everything outside it has none.
It is worth noting how narrow even that list is in terms of study design. The strongest evidence concerns short-term opioid withdrawal, measured within days, in series without control groups. The post-traumatic stress and depression findings come from a single cohort of 30 people who arranged their own treatment abroad [3]. Describing ibogaine as studied for a condition does not mean the question has been answered for that condition, and for everything outside the list the question has not even been asked.
Parkinson's, MS and other neurological conditions
There is no human study of ibogaine in Parkinson's disease, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis or dementia. The association that generates the interest in Parkinson's is indirect: ibogaine raises GDNF in rodents, a growth factor that supports dopamine-producing neurons, and Parkinson's involves the loss of those neurons.
That connection is weaker than it sounds. The GDNF finding came from 36 rats with six per group, appeared only at the higher of two doses, only at 24 hours, and reached protein level in one brain region at roughly twofold [2]. GDNF has itself been investigated as a Parkinson's treatment in its own right, with results that have not translated into an approved therapy, so even a reliable GDNF increase would not amount to a Parkinson's treatment.
For multiple sclerosis and epilepsy there is not even an indirect mechanistic argument of that kind. There is no preclinical work and no human data, and in the case of epilepsy there is a specific reason for concern rather than optimism, since a prolonged psychoactive state accompanied by metabolic and electrolyte shifts is not a benign setting for someone with a seizure disorder.
OCD, bipolar disorder and eating disorders
Obsessive-compulsive disorder, bipolar disorder and eating disorders have no ibogaine evidence in humans or in animals. Bipolar disorder deserves separate comment because the concern is concrete rather than merely an absence. Strongly psychoactive drugs are generally approached with caution in bipolar disorder because of the possibility of precipitating a manic episode, and nothing in the ibogaine literature addresses that question either way.
Eating disorders raise a different practical problem. Ibogaine treatment commonly involves nausea and vomiting [5], and electrolyte status is central to its cardiac safety, with one protocol requiring potassium within a defined range before dosing [4]. People with eating disorders frequently have abnormal electrolytes and cardiac changes, which places them in the category the screening criteria were designed to identify rather than in a candidate population.
If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.
Find a providerAttention disorders and autism are also asked about and have no evidence of any kind. In the case of attention disorders there is a specific practical conflict: the clinic protocol used for the veteran cohort required stimulants to be withdrawn before dosing [3], which means a person taking stimulant medication would face a washout before treatment rather than treatment for the condition the medication addresses.
Chronic pain
Chronic pain is asked about often, partly because of ibogaine's interaction with opioid receptors and partly because many people with chronic pain have become dependent on opioids prescribed for it. Those are two distinct questions and only the second connects to the evidence.
For opioid dependence arising from pain treatment, the existing withdrawal literature applies, with all its limitations. For pain itself there is no evidence. The relevant pharmacology points away from an analgesic effect in any case: across three laboratories, ibogaine and noribogaine behaved as mu-opioid antagonists rather than agonists, and ibogaine stimulated G protein binding in no receptor-expressing cell line tested [2]. A compound blocking the mu receptor would not be expected to relieve pain through it, and might complicate the use of opioid analgesics.
When a condition is an exclusion, not an indication
This is the point most worth carrying away. Reading the methods sections of the studies shows that several frequently asked-about conditions functioned as reasons to keep people out.
The clinic protocol used for the veteran cohort excluded cardiovascular, liver or kidney history, psychosis and neurological disorder [3]. The Dutch study excluded severe liver or kidney dysfunction, along with a QT interval above defined thresholds and any QT-prolonging or CYP2D6-affecting medication [4]. The St Kitts series excluded cardiovascular and liver pathology, a resting heart rate below 50 beats per minute, and long QT syndrome [5].
Neurological disorder as a blanket exclusion is the striking one. The researchers who conducted the work that generates interest in neurological applications specifically declined to enrol people with neurological conditions. That was a safety judgement, made by people with the best available understanding of the drug, and it is a considerably stronger signal than the absence of positive evidence on its own.
The pattern across these exclusion lists is consistent and tells its own story. What the studies screened out was liver and kidney disease, because those organs clear the drug; cardiac disease and conduction abnormality, because of the hERG effect; psychosis, because of the psychoactive load; and neurological disorder, because the drug acts on the nervous system in ways that are not fully characterised. Each exclusion maps onto a known property of ibogaine, which means they were not arbitrary caution but reasoned judgements about specific risks.
An important consequence follows for anyone reading claims about these conditions. A provider offering ibogaine for a neurological or psychiatric condition on this list is not merely working beyond the evidence. They are working against the explicit screening judgement of every published protocol, which is a different and more serious position than operating in an unstudied area.
Why absence of evidence matters here
With a low-risk intervention, trying something unstudied carries limited cost. Ibogaine is not low risk. In a closely screened cohort, maximum QT prolongation averaged 95 milliseconds, 7 of 14 patients passed 500 milliseconds, in 6 of 14 the abnormality persisted beyond 24 hours, and all 14 were temporarily unable to walk unaided [4]. The drug blocks the hERG potassium channel in heart muscle at relevant concentrations [8], and fatalities are documented, chiefly in unsupervised settings [7].
That risk is constant regardless of why someone takes it. The case for accepting it rests entirely on the expected benefit, and where no evidence of benefit exists for a condition, there is nothing on the other side of the comparison. A 2026 scoping review also identifies the lack of standardised dosing, harmonised outcome measures and systematic long-term follow-up as structural limitations of the field [6], which means even the studied indications rest on shakier ground than is often assumed.
How claims appear anyway
Claims about these conditions circulate despite the absence of data, and they are usually built in one of three ways. The first is extrapolation from the neuroplasticity literature, reasoning that a drug promoting plasticity should help any condition involving the brain. The second is extrapolation from the veteran cohort, where a traumatic brain injury history leads to claims about neurological conditions generally, although what was measured there was psychiatric symptoms [3]. The third is testimonial, which carries no information about whether an effect exists.
A useful test is to ask what measurement supports a specific claim, in how many people, with what comparison. For every condition in this entry the answer is that there is none, and a provider or page unable to produce one is making a claim rather than reporting a finding, however familiar the surrounding language sounds.
None of this means these conditions could never be studied, and some of them may eventually be. A 2026 review of emerging treatments argues that trials in this field need active comparators, formal blinding checks and blinded objective endpoints [7], and those standards would apply to any new indication. Until such work exists, the accurate answer to each question in this entry is the same: nobody knows whether it would help, and the cardiac risk described above is entirely unchanged by that uncertainty.
Frequently asked questions
Is ibogaine used for Parkinson's disease?
There is no human study. The interest comes from ibogaine raising GDNF in rats, a finding from six animals per group at the higher of two doses, at one time point, confirmed at protein level in one region [2].
What about bipolar disorder?
No evidence exists. The clinic protocol used for the most cited cohort excluded psychosis, and strongly psychoactive drugs are generally approached cautiously in bipolar disorder [3].
Does ibogaine treat chronic pain?
No evidence exists, and the pharmacology points the other way: ibogaine and noribogaine acted as mu-opioid antagonists rather than agonists across three laboratories [2].
Could a provider still offer treatment for these conditions?
Some do. Doing so goes beyond the absence of evidence and against the screening judgement of the published protocols, which excluded neurological disorder, psychosis, and cardiac, liver and kidney disease [3] [4] [5].
Why were neurological conditions excluded from studies?
As a safety judgement. The clinic treating the veteran cohort excluded neurological disorder along with cardiovascular, liver and kidney history and psychosis [3].
References
- Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197
- Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
- Cherian KN, Keynan JN, Anker L, et al. 2024, Nat Med 30(2):373-381. doi:10.1038/s41591-023-02705-w. PMID 38182784. PMC10878970. europepmc.org/article/PMC/PMC10878970
- Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1). doi:10.1111/add.15448. PMC9292417. europepmc.org/article/PMC/PMC9292417
- Mash DC, Duque L, Page B, Allen-Ferdinand K. 2018, Front Pharmacol 9:529. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00529/full
- Esperanca MP, Gomes NGM, Campos MG. 2026, Molecules 31(3):545. doi:10.3390/molecules31030545. PMID 41683522. PMC12899015. europepmc.org/article/PMC/PMC12899015
- Shen MR, Owusu-Boaitey K, Murphy ZD, et al. 2026, Front Psychiatry 17:1909149. doi:10.3389/fpsyt.2026.1909149. PMID 42755825. PMC13581858. frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2026.1909149/full
- Koenig X, Hilber K. 2015, Molecules 20(2):2208-2228. doi:10.3390/molecules20022208. PMC4382526. mdpi.com/1420-3049/20/2/2208